Trial record 8 of 54 for:    "Patent ductus arteriosus"

Adding Paracetamol to Ibuprofen for Treatment of Patent Ductus Arteriosus in Preterm Infants

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified July 2014 by Rambam Health Care Campus
Sponsor:
Information provided by (Responsible Party):
Rambam Health Care Campus
ClinicalTrials.gov Identifier:
NCT02002741
First received: November 24, 2013
Last updated: July 23, 2014
Last verified: July 2014
  Purpose

The purpose of this study is to determine if adding paracetamol to ibuprofen is superior to ibuprofen only for treatment of patent ductus arteriosus (PDA) in preterm infants.


Condition Intervention Phase
Hemodynamically Significant Patent Ductus Arteriosus in Preterm Infants
Drug: Paracetamol
Drug: Placebo
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Adding Paracetamol to Ibuprofen for Treatment of Patent Ductus Arteriosus in Preterm Infants: A Pilot, Double Blind, Randomized, Placebo-control Trial

Resource links provided by NLM:


Further study details as provided by Rambam Health Care Campus:

Primary Outcome Measures:
  • The incidence of patent ductus arteriosus closure [ Time Frame: 3-10 days after first dose of Ibuprofen + study drug ] [ Designated as safety issue: No ]
    By echocardiography


Secondary Outcome Measures:
  • Adverse effects [ Time Frame: until discharge home (usually within 2-3 months since recruitment) ] [ Designated as safety issue: Yes ]
    Renal and liver function, gastrointestinal complications will be assessed from the patient's medical records

  • The need for surgical ligation for PDA [ Time Frame: 3-21 days after first dose of Ibuprofen + study drug ] [ Designated as safety issue: No ]
    need for surgical ligation for PDA


Estimated Enrollment: 50
Study Start Date: August 2014
Estimated Study Completion Date: February 2017
Estimated Primary Completion Date: May 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Ibuprofen + Paracetamol

Ibuprofen 10mg/kg once --> 5mg/kg twice, q 24h for total of 3 doses

+ Intravenous Paracetamol : Loading dose 20mg/kg --> 10 mg/kg q6h for total of 12 doses

Drug: Paracetamol
Ibuprofen 3 doses administered q24h + Paracetamol 12 doses administered q 6h
Other Names:
  • Acetaminophen
  • Acamol
Placebo Comparator: Ibuprofen + Placebo

Ibuprofen 10mg/kg once --> 5mg/kg twice, q 24h for total of 3 doses

+ Placebo (NaCl 0.9%) , Intravenous , at equal volume to the paracetamol in the paracetamol arm, total of 12 doses given q 6h.

Drug: Placebo
Ibuprofen 3 doses administered q24h + Placebo : 12 doses administered q 6h
Other Name: NaCl 0.9%

  Eligibility

Ages Eligible for Study:   up to 2 Months
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Preterm infants born at 24-37 gestational age
  • diagnosis of Hemodynamically significant patent ductus arteriosus
  • Medical staff decided to treat with Ibuprofen
  • Parents have signed informed consent

Exclusion Criteria:

  • Contraindication for ibuprofen
  • Alanine transaminase /Aspartate transaminase≥ 200 U/L
  • Significant congenital heart disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02002741

Contacts
Contact: Ori Hochwald, MD 972-4-8542219 o_hochwald@rambam.health.gov.il

Locations
Israel
Rambam Medical Center Not yet recruiting
Haifa, Israel, 31096
Contact: Ori Hochwald, MD    972-4-8542219    o_hochwald@rambam.health.gov.il   
Sponsors and Collaborators
Rambam Health Care Campus
  More Information

No publications provided

Responsible Party: Rambam Health Care Campus
ClinicalTrials.gov Identifier: NCT02002741     History of Changes
Other Study ID Numbers: IBUACA CTIL
Study First Received: November 24, 2013
Last Updated: July 23, 2014
Health Authority: Israel: Ethics Commission

Keywords provided by Rambam Health Care Campus:
patent ductus arteriosus
PDA
Preterm
Infant
Electrocardiography
Paracetamol
Acamol
ibuprofen
Placebo

Additional relevant MeSH terms:
Ductus Arteriosus, Patent
Heart Defects, Congenital
Cardiovascular Abnormalities
Cardiovascular Diseases
Heart Diseases
Congenital Abnormalities
Acetaminophen
Ibuprofen
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Antipyretics
Anti-Inflammatory Agents, Non-Steroidal
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on August 26, 2014